Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma

Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma

<b>Background/Objectives</b>: Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and poor prognosis, largely owing to its heterogeneity and the involvement of multiple intracellular signaling pathways that contribute to drug resistance. While recent advancemen...

Full description

Saved in:
Bibliographic Details
Main Authors: Muhammad Furqan, Richard J. R. Elliott, Peter W. K. Nagle, John C. Dawson, Roza Masalmeh, Virginia Alvarez Garcia, Alison F. Munro, Camilla Drake, Gillian M. Morrison, Steven M. Pollard, Daniel Ebner, Valerie G. Brunton, Margaret C. Frame, Neil O. Carragher
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Pharmaceutics
Subjects:
focal adhesion kinase (FAK)
MEK
glioblastoma
tumor heterogeneity
combination therapy
chemogenomic screening
Online Access:https://www.mdpi.com/1999-4923/17/5/549
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/17/5/549

Similar Items